The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month data Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures ...

Extends US patent protection until 2042MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the ...

Allay Therapeutics has dosed the first subject in the randomised Phase IIb registration trial of its investigational analgesic, ATX101, designed to provide extended pain relief following total knee ...

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with (NSCLC), if approved The application for this investigational treatment is based on positive ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Bayer's subsidiary AskBio received approval from the U.S. drug regulator to accelerate the development of its investigational gene therapy to treat moderate-stage Parkinson's disease.